FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| One-year outcomes by index treatment in older patients with acute cholecystitis. Protocol of the international, prospective, observational GOLDENEYE study. PMID 41448354 · Cir Esp (Engl Ed) · 2026-Jun This is a protocol for an international, prospective, observational study comparing management strategies (supportive care, drainage, cholecystectomy) for acute cholecystitis in elderly patients. It is not oncology, is not randomized, does not involve a drug-containing intervention as a primary comparison, and does not report time-to-event efficacy results. It is a protocol-only publication. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability. PMID 41423716 · Ann Clin Transl Neurol · 2026-Jun 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of Desloratadine on Treatment Response and Inflammation During Neoadjuvant Chemotherapy in Stage II-III Breast Cancer: A Randomized Pilot Study. PMID 41223739 · Arch Med Res · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Lymph node dissection based on 18F-PSMA PET/CT during radical prostatectomy for intermediate and high risk prostate cancer: interim results of a prospective, randomized study. PMID 40999072 · Prostate Cancer Prostatic Dis · 2026-Jun The study is a randomized trial of a surgical/procedural intervention (lymph node dissection) for prostate cancer and lacks a drug-containing intervention, which is a required criterion for eligibility. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Management of Anemia in Lower-Risk Myelodysplastic Syndromes/Neoplasms With Novel Agents. PMID 40763320 · JCO Oncol Pract · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A multi-site feasibility study of a stepped-care telehealth intervention for depression and anxiety in post-treatment cancer survivors at community cancer clinics (WF-30917CD). PMID 39810026 · J Cancer Surviv · 2026-Jun The study is a randomized controlled trial in human cancer survivors, but it is a feasibility study (not Phase III/IIIb or Phase II/III), evaluates a non-drug psycho-oncology intervention (telehealth CBT), and uses patient-reported outcome measures (depression, anxiety, QOL) rather than time-to-event efficacy endpoints (OS, PFS, DFS, etc.). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol. PMID 42515859 · BJU Int · 2026-Jul-27 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Identifying subsets of patients with retroperitoneal sarcoma who benefit from radiotherapy: an Interpretable AI reanalysis of the STRASS randomised trial. PMID 42509079 · Lancet Digit Health · 2026-Jul-27 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Circulating Tumour DNA and Molecular Residual Disease in Oesophageal Cancer: Clinical Readiness, Evidence Gaps and Trial-Ready Applications. PMID 42508592 · Crit Rev Oncol Hematol · 2026-Jul-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801). PMID 42507969 · J Clin Oncol · 2026-Jul-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer. PMID 42507968 · J Clin Oncol · 2026-Jul-27 The record describes a published, original, primary analysis of a phase III randomized trial in human oncology with a drug intervention and time-to-event efficacy endpoints. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX. PMID 42269244 · Eur J Cancer · 2026-Jul-26 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
B
|
旧查询独有 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial. PMID 42241967 · Eur J Cancer · 2026-Jul-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review. PMID 42235464 · Eur J Cancer · 2026-Jul-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Multicenter randomized effectiveness/implementation trial of a digital self-management support tool to improve the quality of life during adjuvant hormonal therapy for patients with early breast cancer: The HOPE trial. PMID 42501860 · Contemp Clin Trials · 2026-Jul-25 The record describes a Phase-unspecified randomized trial protocol (no results) with a drug intervention (adjuvant endocrine therapy) and a primary quality-of-life endpoint. It does not report original formal results for a time-to-event efficacy endpoint as required. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prioritizing Chemotherapy in Total Neoadjuvant Therapy Improves pCR Rate in Locally Advanced Rectal Cancer in Countries with Limited Radiotherapy Access: A Randomized Controlled Trial. PMID 42501213 · J Gastrointest Cancer · 2026-Jul-25 The record describes a randomized trial in oncology with a drug intervention and a time-to-event secondary endpoint (OS), but the phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata. Furthermore, the primary efficacy endpoint is pathological complete response (pCR), which is not a time-to-event endpoint. While OS is a time-to-event endpoint, it is reported as an exploratory secondary outcome with immature results. Therefore, the trial does not meet the eligibility criteria for a definitive randomized trial with a primary/key secondary time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| On Hierarchical Composite Endpoints in Pediatric Cancer Supportive Care: Illustrative Examples From Two Multi-Center Phase-III Randomized Clinical Trials. PMID 42499270 · Pediatr Blood Cancer · 2026-Jul-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial. PMID 42498834 · Leukemia · 2026-Jul-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
H
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Blood-based cell-free DNA for addressing colorectal cancer screening disparities: a study protocol for a randomised trial. PMID 42498482 · BMJ Open · 2026-Jul-24 方案论文未报告临床试验结果。 |
H
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Rocbrutinib, a Highly Selective Fourth-Generation Covalent and Noncovalent BTK Inhibitor, in R/R Non-GCB DLBCL: Efficacy and Safety from a Phase I Study. PMID 42496861 · Adv Ther · 2026-Jul-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
H
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Acute skin toxicity and cosmesis outcome in non-metastatic breast cancer patients treated with ultrahypofractionated radiotherapy: a randomized controlled phase II clinical trial comparing proton versus photon radiotherapy. PMID 42183732 · J Radiat Res · 2026-Jul-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol 2026;89:437-45. PMID 42493340 · Eur Urol · 2026-Jul-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Re: James P. Buteau, Daniel Moon, Michael T. Fahey, et al. Effect of [68Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Clinically High-risk Non-suspicious Findings on Multiparametric MRI (PRIMARY2): A Multicenter, Non-inferiority, Phase 3, Randomized Controlled Trial. Lancet Oncol 2026;27:839-848. PMID 42493339 · Eur Urol · 2026-Jul-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial. PMID 42493213 · J Immunother Cancer · 2026-Jul-23 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
H
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Exploring the Feasibility, Acceptability, and Safety of a 4:3 Intermittent Fasting Weight Loss Program Among Stage I-III Breast Cancer Survivors With Overweight or Obesity: Protocol for a 6-Month Proof-of-Concept Feasibility Trial. PMID 42492498 · JMIR Res Protoc · 2026-Jul-23 This is a protocol for a proof-of-concept feasibility trial investigating a behavioral weight-loss intervention (intermittent fasting and exercise) among breast cancer survivors. It is not a randomized Phase III trial, does not involve a drug intervention, and does not report time-to-event efficacy outcomes. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial. PMID 42489705 · Clin Cancer Res · 2026-Jul-23 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
H
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| First Measurement: Proactively Sparing the Immune System During SBRT to Early-Stage Lung Cancer-A Randomized Phase II Study. PMID 42486309 · Int J Radiat Oncol Biol Phys · 2026-Jul-22 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
H
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Technical Aspects of Pancreatectomy in the Alliance A021501 Multicenter Clinical Trial of Neoadjuvant Therapy for Pancreatic Cancer: Surgical and Pathologic Documentation. PMID 42485590 · JCO Oncol Pract · 2026-Jul-22 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
H
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Eribulin versus taxane as first-line chemotherapy combined with dual HER2 blockade in patients with HER2-positive locally advanced or metastatic breast cancer: final survival outcomes of the JBCRG-M06/EMERALD study. PMID 42480197 · ESMO Open · 2026-Jul-21 The record explicitly describes a Phase III randomized trial with a drug-containing intervention and primary time-to-event efficacy endpoints (PFS, OS) with hazard ratios and survival rates, meeting all eligibility criteria. |
H
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | confirmed 4 Figure · 7 Panel · risk visible |
| Preoperative single-dose systemic steroid in major head and neck surgery (J-SUPPORT 2002, PreSte-HN Study): a phase III, placebo-controlled, randomized, double-blind study. PMID 42479256 · Int J Clin Oncol · 2026-Jul-21 The study meets criteria for oncology, human, randomized, phase III, drug intervention, and original result. However, it does not include a primary or key secondary time-to-event efficacy endpoint as defined (e.g., OS, PFS, DFS, HR, Kaplan-Meier), so it is ineligible. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of cetuximab-irinotecan rechallenge versus regorafenib in ras wild-type metastatic colorectal cancer: a single-center exploratory randomized trial. PMID 42477619 · BMC Cancer · 2026-Jul-21 The study is a randomized, drug-intervention oncology trial with a time-to-event primary endpoint (PFS). However, it is explicitly described as an 'exploratory randomized trial' and its phase is not stated as Phase III/IIIb or Phase II/III in the abstract. The eligibility criteria require explicit establishment of Phase III/IIIb or Phase II/III status, which is not met here. The study is also described as exploratory and of small sample size (n=68), further suggesting it is not a definitive trial. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial. PMID 42476886 · Eur Urol · 2026-Jul-20 The report is from a Phase 3 randomized trial in oncology (prostate cancer) but focuses on patient-reported outcomes (quality-of-life/safety) after radiotherapy, which is a non-drug intervention. It does not report a primary or key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, or any Kaplan-Meier/HR analysis. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Strengthening awareness and community resources for early detection of lung cancer through navigation guided screening in American Indian/Alaska Native clinics (SACRED LUNGS): Study protocol. PMID 42476254 · Contemp Clin Trials · 2026-Jul-20 方案论文未报告临床试验结果。 |
H
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Optimizing prostate biopsy decision making - (MUSIC-screen): A 1:1 randomized controlled trial comparing micro-ultrasound versus multiparametric magnetic resonance imaging for prostate cancer diagnosis. PMID 42476253 · Contemp Clin Trials · 2026-Jul-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Adjuvant aspirin for colorectal cancer with PIK3CA-mutated and COX-2 overexpressed tumours: the ASCOLT translational research study and meta-analysis. PMID 42475879 · EBioMedicine · 2026-Jul-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial. PMID 42473780 · Arthritis Rheumatol · 2026-Jul-20 The study is a Phase 3 randomized trial of a drug (deucravacitinib) with primary results, but it is for psoriatic arthritis (not a human malignant neoplasm) and its primary/secondary endpoints are response rates (ACR20, HAQ-DI, etc.), not time-to-event outcomes like OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR analyses. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Role of Locoregional Treatment in Non-Progressive De Novo Metastatic Breast Cancer under Systemic Treatment: A Randomized Controlled Trial (LTMBC). PMID 42472751 · Ann Surg Oncol · 2026-Jul-20 The record describes a randomized oncology trial with a drug-containing intervention and a primary time-to-event efficacy endpoint (OS). However, the explicit trial phase is not stated in the title, abstract, or metadata. Phase cannot be inferred from the study design or context. Therefore, eligibility is indeterminate. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data. PMID 42172567 · J Clin Oncol · 2026-Jul-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. PMID 42150145 · J Clin Oncol · 2026-Jul-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117). PMID 42471483 · Br J Cancer · 2026-Jul-18 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment. PMID 42470850 · Cancer Treat Res Commun · 2026-Jul-18 The record describes an exploratory subgroup analysis within a larger randomized trial, not the primary results of a Phase III/IIIb or Phase II/III trial. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Milk of magnesia in enhanced recovery after surgery for preventing postoperative ileus after hysterectomy: randomized controlled trial. PMID 42470487 · Support Care Cancer · 2026-Jul-18 The study is a randomized trial in an oncology population but does not meet key eligibility criteria: the intervention is not an anticancer drug (milk of magnesia), and the endpoints are not time-to-event oncology efficacy endpoints. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A clinical study on fall risk assessment and preventive nursing in older adults with non-Hodgkin's lymphoma undergoing chemotherapy-a randomized controlled trial. PMID 42470465 · Support Care Cancer · 2026-Jul-18 The record describes a randomized trial in oncology patients receiving chemotherapy, but the primary endpoint is fall incidence, not a time-to-event efficacy endpoint (like OS or PFS). The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III. Therefore, it does not meet the eligibility criteria for a Kaplan-Meier digitization cohort focused on drug efficacy time-to-event outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Study protocol of the C-SOLVE (JACCRO GC-12) trial; a randomized, non-comparative phase II trial of CapeOX or SOX plus zolbetuximab in HER2-negative, CLDN18.2-positive unresectable advanced gastric or esophagogastric junction cancer. PMID 42464196 · BMC Cancer · 2026-Jul-17 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition. PMID 42012456 · Clin Cancer Res · 2026-Jul-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial. PMID 42001507 · Clin Cancer Res · 2026-Jul-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Use of ctDNA in Older Women with ER+ Breast Cancer to Facilitate Surgical De-escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies. PMID 41854411 · Clin Cancer Res · 2026-Jul-17 The record is a prospective, single-arm trial (n=43) of primary endocrine therapy (pET) with correlative ctDNA analysis. It is not a randomized trial, does not involve a drug-containing intervention arm compared to another arm, and is not Phase III or Phase II/III. Therefore, it does not meet the core eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Robot-assisted versus open pancreatoduodenectomy for cancer in the pancreatic head (DIPLOMA-2x2): study protocol for an international multicentre patient- and assessor-blinded randomized controlled non-inferiority trial. PMID 42464359 · Trials · 2026-Jul-16 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Re: Effect of [68Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Clinically High-risk Non-suspicious Findings in Multiparametric MRI (PRIMARY2): A Multicentre, Non-inferiority, Phase 3, Randomised Controlled Trial. PMID 42463362 · Eur Urol · 2026-Jul-16 The record describes a Phase 3 randomized controlled trial in oncology (prostate cancer), but lacks an abstract and specific details. Key criteria (human subject, drug intervention, time-to-event endpoint, original result) cannot be established from the provided metadata. The title indicates a diagnostic imaging intervention ([68Ga]Ga-PSMA-11 PET-CT), which may not be a 'drug-containing intervention' as defined for this cohort, but this is uncertain. The primary endpoint is not specified as time-to-event (e.g., OS, PFS). Therefore, eligibility cannot be determined. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of silver diamine fluoride in preventing radiation-induced caries: A pilot study. PMID 42461172 · J Am Dent Assoc · 2026-Jul-16 The study is a randomized, placebo-controlled trial in oncology (prevention of radiation-induced caries in head and neck cancer patients). However, the intervention (silver diamine fluoride) is a topical preventive dental agent, not a drug-containing anticancer intervention. The primary endpoint is caries increment (a count/surfaces outcome), not a time-to-event endpoint like OS or PFS. Therefore, it does not meet the criteria for inclusion in the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |